podqast
The Peter Attia DrivePeter Attia, MDAll episodes

#118 - Lloyd Klickstein, M.D., Ph.D.: Rapamycin, mTOR inhibition, and the biology of aging

2h 15m
AboutScience
Hosted byPeter Attia

Lloyd Klickstein is the Chief Science Officer at resTORbio, a biopharmaceutical company that develops medications to target the biology of aging. In this episode, Lloyd discusses his company's clinical application of rapamycin and its derivatives. He also elucidates details of his 2014 paper—a paper that greatly influenced Peter's perspective of rapamycin in the context of longevity. Peter and Lloyd go on to discuss the dose-dependent effect of rapamycin on immune function and compare rapamycin, fasting, and caloric restriction. We discuss: • His background and decision to leave academia for translational medicine [6:15];

Learn more: https://peterattiamd.com/ Show notes page for this episode: https://peterattiamd.com/LloydKlickstein Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on Facebook | Twitter | Instagram.

Shows like The Peter Attia Drive
Huberman LabThe Dylan Gemelli PodcastThe Diary Of A CEO with Steven BartlettConversationsModern WisdomThe Dom Harvey PodcastWhat's Up Docs? RomanianConsulta Aberta PortugueseMétamorphose, éveille ta conscience ! French
Also about science
Every episode about Science
More from The Peter Attia Drive